Safety Assessment of Intravenous Administration of Trastuzumab in 100ml Saline for the Treatment of HER2-Positive Breast Cancer Patients |
Abe, Hajime
(Breast Center, Bell Land General Hospital)
Mori, Tsuyoshi (Division of Breast and General Surgery, Shiga University of Medical Science) Kawai, Yuki (Division of Breast and General Surgery, Shiga University of Medical Science) Tomida, Kaori (Division of Breast and General Surgery, Shiga University of Medical Science) Yamazaki, Keiichi (Breast Center, Bell Land General Hospital) Kubota, Yoshihiro (Division of Breast and General Surgery, Shiga University of Medical Science) Umeda, Tomoko (Division of Breast and General Surgery, Shiga University of Medical Science) Tani, Tohru (Department of Surgery, Shiga University of Medical Science) |
1 | Tan-Chiu E, Yothers G, Romond E, et al (2005). Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol, 23, 7811-9. DOI ScienceOn |
2 | Trotti A, Colevas AD, Setser A, et al (2003). CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 13, 176-81 DOI ScienceOn |
3 | Bang YJ, Van Cutsem E, Feyereislova A, et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 28, 687-97 |
4 | Bardin C, Astier A, Vulto A, et al (2011). Guidelines for the practical stability studies of anticancer drugs: a European consensus conference. Ann Pharm Fr, 69, 221-31. DOI |
5 | Cook-Bruns N (2001). Retrospective analysis of the safety of herceptin immunotherapy in metastatic breast cancer. Oncology, 61, 58-66. DOI ScienceOn |
6 | Halyard MY, Pisansky TM, Dueck AC, et al (2009). Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol, 27, 2638-44. DOI ScienceOn |
7 | Lenz HJ (2007). Management and preparedness for infusion and hypersensitivity reactions. The Oncologist, 12, 601-9. DOI ScienceOn |
8 | Leyland-Jones B, Gelmon K, Ayoub JP (2003). Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol, 21, 3965-71. DOI ScienceOn |
9 | Owens MA, Horten BC, Da Silva MM (2004). HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer, 5, 63-9. DOI ScienceOn |
10 | Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer; correlation of relapse and survival with amplification of the HER2/neu oncogene. Science, 235, 177-82. DOI ScienceOn |
11 | Slamon DJ, Leyland-Jones B, Shak S, et al (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 783-92. DOI ScienceOn |
12 | Slamon D, Eiermann W, Robert N, et al (2011). Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med, 365, 1273-83. DOI ScienceOn |
13 | Suter TM, Procter M, van Veldhuisen DJ, et al (2007). Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol, 25, 3859-65. DOI ScienceOn |
![]() |